Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Letrozole,LtzStudy001,2021,USA,MDV,350,68,99.5,0.5,28.5,12,85,5,25,40,20,15,60,25,10,5,30,40,20,18,6,4,9,3,8,45,55,AC,TC,CMF,Taxol,10,75,15,15,25,30,20,50,30,60,2
Letrozole,LtzStudy002,2022,Canada,Claim Database,420,72,99.7,0.3,30.1,15,78,3,28,38,22,12,55,30,10,5,25,45,20,20,8,5,11,4,10,50,60,FEC,Docetaxel,AC-TH,Taxotere,8,70,22,18,28,35,15,55,30,70,3
Letrozole,LtzStudy003,2023,UK,MDV,280,65,99.6,0.4,27.9,10,90,7,30,35,25,10,65,20,10,5,35,35,20,15,5,3,8,2,5,40,50,EC,Cyclophosphamide,FEC-D,Doxorubicin,12,80,8,12,22,28,25,45,30,55,1
Letrozole,LtzStudy004,2024,Australia,Claim Database,480,70,99.8,0.2,29.5,13,82,4,27,39,21,13,58,28,9,5,28,42,20,19,7,4,10,3,9,48,58,AT,Carboplatin,Taxol-CMF,Methotrexate,9,72,19,17,27,33,18,52,30,65,2
